{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041287","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.349628+00:00","generated_at":"2026-06-11T18:44:34.665910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology Q2 net loss $34.2M; terminates MDS/AML programs, delays ALTA-002 IND","bullets":["GAAP net loss $34.2M ($0.84/share); non-GAAP net loss $27.9M vs $27.1M prior year.","Cash $224.5M; funding expected through mid-2025 plus $40M term loan availability.","Terminating ASPEN-02 (MDS) and ASPEN-05 (AML); evorpacept+azacitidine did not improve outcomes.","ASPEN-06 (gastric cancer) on track for Q4 2023 data update; EU orphan drug designation received.","ALTA-002 IND delayed to Q1 2024 due to CMC issues; ADC platform expansion deferred."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041287","json":"https://secwatch.observer/filing/0000950170-23-041287.json","markdown":"https://secwatch.observer/filing/0000950170-23-041287.md","text":"https://secwatch.observer/filing/0000950170-23-041287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/0000950170-23-041287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/alxo-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:44:34.665910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd6c397ded8b5f2deb14ea73058d811999905909","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/0000950170-23-041287-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}